Long term results of EORTC trial for patients with resectable liver metastases from colorectal cancer

(European Organisation for Research and Treatment of Cancer) Long term results of the randomized phase III EORTC intergroup trial 40983 were recently reported in The Lancet Oncology. The observed 4.1 percent difference in overall survival at five years for patients with initially resectable liver metastases from colorectal cancer was not significant for perioperative chemotherapy with FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin) compared with surgery alone. The authors conclude that perioperative chemotherapy with FOLFOX4 should remain the reference treatment for this population of patients.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news